Selecta Biosciences is one of the most mature companies in an area attracting the attention of industry titans.

The leading gene therapy developer just bolstered its technology platform.

Gene therapy and gene editing get all the glory, but investors shouldn't overlook an emerging group of tools.

The share price dipped below $1 -- into penny stock territory -- but analysts are optimistic they'll recover.

Barclays made a list of 35 stocks with overweight ratings that it expects to benefit from strong earnings next year.

Sarepta's trial supports its drug's 'potentially differentiated profile' to treat Duchenne muscular dystrophy, the company said. The stock is higher.

Stocks moving in premarket trading Friday include Boeing, Micron, Pfizer, Sarepta and Moderna.

Sarepta shares lose half their value after a gene-therapy study seen as a shoo-in treatment for Duchenne muscular dystrophy produces disappointing results.

Cramer says buyers are betting science will beat the virus. Here are the companies that can light the way forward.

Universal Studios has begun construction on Epic Universe, its third theme park planned for Florida.

The e-commerce giant has just made a decision that suggests the health of the economy is not improving.

The Tesla CEO has put his offer for Twitter back on the table. And as rich as he is, investors are worried.